Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
Provided By GlobeNewswire
Last update: Mar 11, 2025
SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2024.
Read more at globenewswire.com
